Christine Fink1, Claudia Jaeger2, Katharina Jaeger2, Holger A Haenssle1,3. 1. Department of Dermatology, Venereology, and Allergology, University Medical Center, Ruprecht-Karl University, Heidelberg, Germany. 2. Dermatology Practice, Heidelberg, Germany. 3. Former affiliation: Department of Dermatology, Venereology, and Allergology, University Medical Center, Georg-August University, Goettingen, Germany.
Abstract
BACKGROUND: MelaFind is a multispectral computer vision system intended to -provide additional information on melanocytic lesions suspected of being melanoma by -objectively assessing their three-dimensional morphology. OBJECTIVES: Analysis of the diagnostic performance of MelaFind in a real-life clinical setting. PATIENTS AND METHODS: In this observational study, 360 pigmented skin lesions (PSL) in 111 patients were assessed by office-based dermatologists using MelaFind. Scores ≥ 2 were considered to be suspicious of malignancy. The decision for surgical excision was left to the discretion of the examining dermatologists. RESULTS: MelaFind scores ≥ 2 were observed in 147 of 360 PSL (40.8 %). Of the 107 excised lesions with a MelaFind-score ≥ 2, the diagnosis of melanoma was made in three cases; 53 (49.5 %) lesions proved to be dysplastic nevi. Among all lesions biopsied (n = 113), the sensitivity and specificity of MelaFind was 100 % and 5.5 %, respectively. While a higher specificity of 68.5 % may be assumed with respect to the overall data set (n = 360), this assumption is limited by incomplete follow-up data required to confirm that all non-excised lesions with a score < 2 were actually benign. CONCLUSION: The high sensitivity of MelaFind facilitated the detection of melanoma. The overall specificity and benign-to-malignant ratio of excised lesions were acceptable. These parameters may be improved by using higher cutoff scores for excisional biopsies, and by more vigorously selecting PSL for MelaFind examination.
BACKGROUND:MelaFind is a multispectral computer vision system intended to -provide additional information on melanocytic lesions suspected of being melanoma by -objectively assessing their three-dimensional morphology. OBJECTIVES: Analysis of the diagnostic performance of MelaFind in a real-life clinical setting. PATIENTS AND METHODS: In this observational study, 360 pigmented skin lesions (PSL) in 111 patients were assessed by office-based dermatologists using MelaFind. Scores ≥ 2 were considered to be suspicious of malignancy. The decision for surgical excision was left to the discretion of the examining dermatologists. RESULTS:MelaFind scores ≥ 2 were observed in 147 of 360 PSL (40.8 %). Of the 107 excised lesions with a MelaFind-score ≥ 2, the diagnosis of melanoma was made in three cases; 53 (49.5 %) lesions proved to be dysplastic nevi. Among all lesions biopsied (n = 113), the sensitivity and specificity of MelaFind was 100 % and 5.5 %, respectively. While a higher specificity of 68.5 % may be assumed with respect to the overall data set (n = 360), this assumption is limited by incomplete follow-up data required to confirm that all non-excised lesions with a score < 2 were actually benign. CONCLUSION: The high sensitivity of MelaFind facilitated the detection of melanoma. The overall specificity and benign-to-malignant ratio of excised lesions were acceptable. These parameters may be improved by using higher cutoff scores for excisional biopsies, and by more vigorously selecting PSL for MelaFind examination.
Authors: Stig Uteng; Eduardo Quevedo; Gustavo M Callico; Irene Castaño; Gregorio Carretero; Pablo Almeida; Aday Garcia; Javier A Hernandez; Fred Godtliebsen Journal: Sensors (Basel) Date: 2021-01-20 Impact factor: 3.576
Authors: Yating Zhang; Xiaoqian Wu; Li He; Chan Meng; Shunda Du; Jie Bao; Yongchang Zheng Journal: Transl Cancer Res Date: 2020-02 Impact factor: 1.241